Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Some Tumors Found to Contain Factors that May Suppress Metastasis

By BiotechDaily International staff writers
Posted on 29 Nov 2011
Scientists are closer to determining what drives tumor metastasis, as laboratory mice models suggest there are factors inside tumors that can inhibit their own growth.

In the November 15, 2011, issue of the Cancer Research, a journal of the American Association for Cancer Research (AACR), Raúl A. Ruggiero, PhD, a biologic researcher at the division of experimental medicine at the National Academy of Medicine in Buenos Aires, Argentina, described this innovative process.

Dr. Ruggiero and colleagues used bioanalytic techniques of ion electrospray mass and tandem mass spectrometry to identify the aspects that lead to metastasis resistance in laboratory models of localized cancer, a phenomenon called “concomitant tumor resistance” in which factors in a tumor can inhibit its own metastasis. “The main cause of death in cancer patients is associated much more with metastasis rather than with the growth of a localized tumor, which generally can be surgically removed,” he said.

Dr. Ruggiero’s laboratory found that the presence of variant forms of the amino acid tyrosine were responsible for concomitant tumor resistance. In tumor models where these variants of tyrosine were present, the localized tumor did not tend to metastasize as fast as tumors lacking the variants.

Currently, tumor metastasis is treated with a variety of chemotherapy regimens, but Dr. Ruggiero said the results of this sort of treatment are usually disappointing. He hopes that these tyrosine variants could be developed as a simple and safe type of therapy to block metastatic growth. “Both meta- and ortho-tyrosine have many attractive features. They exert antitumor effects at very low concentrations, are naturally produced in the proper tumor-bearing organism, and do not appear to exert any toxic side effects,” remarked Dr. Ruggiero. “If these findings are confirmed, we could develop new and more harmless means to manage malignant disease.”

Related Links:
American Association for Cancer Research



Channels

Genomics/Proteomics

view channel
Image: Pulsed near infrared light (shown in red) is shone onto a tumor (shown in white) that is encased in blood vessels. The tumor is imaged by photoacoustic tomography via the ultrasound emission (shown in blue) from the gold nanotubes (Photo courtesy of Jing Claussen (iThera Medical, Germany)).

Gold Nanotubes Are Novel Agents for Cancer Diagnosis and Treatment

Cancer researchers have produced a highly defined class of gold nanotubes that are suitable for use in animals as in vivo imaging nanoprobes, photothermal conversion agents, and drug delivery vehicles.... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.